Ian C. Chute

Ian C. Chute

Auto-generated profile, based on publicly available information

Ian C. Chute

Atlantic Cancer Research Institute, Moncton, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2018 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
AJAndrew P. Joy
Andrew P. Joy
DAD. Craig Ayre
D. Craig Ayre
ICIan C. Chute
Ian C. Chute
ABAnnie‐Pier Beauregard
Annie‐Pier Beauregard
Gabriel WajnbergGabriel Wajnberg
Gabriel Wajnberg
DBDavid A. Barnett
David A. Barnett
Sample amount is often a limiting factor for multi‐parametric analyses that encompass at least three areas of ‘‐omics’ research: genomics, transcriptomics and proteomics. Limited sample amounts are also an important consideration when these multi‐parametric analyses are performed on extracellular vesicles (EVs), as the amount of EVs (and EV cargo) that can be isolated is often very low. It is well understood that a monophasic solution of phenol and guanidine isothiocyanate (i.e. TRIzol©) can simultaneously isolate DNA, RNA and proteins from biological samples; however, it is most commonly used for the extraction of RNA. Validation of this reagent for the isolation of multiple classes of biological molecules from EVs would provide a widely applicable method for performing multi‐parametric analyses of EV material. In this report, we describe a comparison of proteins identified from EVs processed with either TRIzol© or the conventional Laemmli buffer protein‐extraction reagents. EVs were isolated from 3 mL of cell‐culture supernatant derived from MCF‐10A, MCF‐7 and MDA‐MB‐231 cells using the Vn96 EV capture technology. For the TRIzol© extraction protocol, proteins were precipitated with acetone from the organic phase and then re‐solubilized in a mixture of 8M urea, 0.2% SDS and 1 M Tris‐HCl pH 6.8, followed by dilution in 5× loading buffer prior to fractionation with 1D SDS‐PAGE. NanoLC‐MS/MS of the trypsin‐digested proteins was used to generate proteomic profiles from EV protein samples extracted with each method. Of the identified proteins, 57.7%, 69.2% and 57.0% were common to both extraction methods for EVs from MCF‐10A, MCF‐7 and MDA‐MB‐231, respectively. Our results suggest that TRIzol© extraction of proteins from EVs has significant equivalence to the traditional Laemmli method. The advantage of using TRIzol© reagent is the ability to accumulate multi‐parametric data (e.g., RNA and protein profiles) on the same limited EV sample while minimizing sample preparation and processing time.

25 May 2017 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
NBNadia Bouhamdani
Nadia Bouhamdani
AJAndrew Joy
Andrew Joy
DBDavid Barnett
David Barnett
KCKevin Cormier
Kevin Cormier
DLDaniel Léger
Daniel Léger
STSandra Turcotte
Sandra Turcotte
Inactivation of the tumor suppressor gene, von Hippel–Lindau (VHL), is known to play an important role in the development of sporadic clear cell renal cell carcinomas (ccRCCs). Even if available targeted therapies for metastatic RCCs (mRCCs) have helped to improve progression‐free survival rates, they have no durable clinical response. We have previously shown the feasibility of specifically targeting the loss of VHL with the identification of a small molecule, STF‐62247. Understanding its functionality is crucial for developing durable personalized therapeutic agents differing from those available targeting hypoxia inducible factor (HIF‐) pathways. By using SILAC proteomics, we identified 755 deregulated proteins in response to STF‐62247 that were further analyzed by ingenuity pathway analysis (IPA). Bioinformatics analyses predicted alterations in 37 signaling pathways in VHL‐null cells in response to treatment. Validation of some altered pathways shows that STF‐62247's selectivity is linked to an important inhibition of mTORC1 activation in VHL‐null cells leading to protein synthesis arrest, a mechanism differing from two allosteric inhibitors Rapamycin and Everolimus. Altogether, our study identified signaling cascades driving STF‐62247 response and brings further knowledge for this molecule that shows selectivity for the loss of VHL. The use of a global SILAC approach was successful in identifying novel affected signaling pathways that could be exploited for the development of new personalized therapeutic strategies to target VHL‐inactivated RCCs.